Momelotinib
Based on 18 publication(s) in Google Scholar
Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.73%
- CAS No.: 1056634-68-4
- Formule: C23H22N6O2
- Masse moléculaire:414.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Momelotinib
More- Cancer Cell. 2026 May 21:S1535-6108(26)00220-5.
- Cancer Cell. 2018 Sep 10;34(3):439-452.e6. [Abstract]
- Cancer Res. 2020 Jan 1;80(1):44-56. [Abstract]
- Nat Commun. 2025 Jul 24;16(1):6777. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Leukemia. 2012 Oct;26(10):2233-44. [Abstract]
- Metabolism. 2025 Apr 4:156259. [Abstract]
- Int J Biol Sci. 2022 Jan 1;18(2):585-598. [Abstract]
- Cell Death Dis. 2022 Dec 27;13(12):1075. [Abstract]
- Cancer Immunol Res. 2016 Jun;4(6):520-30. [Abstract]
- Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- J Pineal Res. 2019 Apr;66(3):e12552. [Abstract]
- J Enzyme Inhib Med Chem. 2025 Dec;40(1):2488127. [Abstract]
- J Biotechnol. 2025 Mar:399:9-18. [Abstract]
- J Clin Lab Anal. 2026 Feb;40(4):e70161. [Abstract]
- Immunol Invest. 2022 Aug;51(6):1582-1597. [Abstract]
- Environ Monit Assess. 2025 Apr 10;197(5):533. [Abstract]
- bioRxiv. 2025 Oct 25.
Customer Validation & Images
-
WB
-
RT-PCR
-
IF
-
WB
-
ELISA
Activité biologique
|
JAK1 11 nM (IC50) |
JAK2 18 nM (IC50) |
JAK3 155 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
1424 nM
Compound: CYT387
|
Antiproliferative activity against IL-6 stimulated wild type mouse BaF3 cells measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against IL-6 stimulated wild type mouse BaF3 cells measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| BaF3 | IC50 |
1500 nM
Compound: CYT387
|
Antiproliferative activity against mouse BaF3 cells harboring JAK2V617F mutant measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against mouse BaF3 cells harboring JAK2V617F mutant measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| BaF3 | IC50 |
200 nM
Compound: CYT387
|
Antiproliferative activity against mouse BaF3 cells harboring MPLW515L measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against mouse BaF3 cells harboring MPLW515L measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| BaF3 | IC50 |
2348 nM
Compound: CYT387
|
Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK3 measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK3 measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| BaF3 | IC50 |
724 nM
Compound: CYT387
|
Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK2 measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against mouse BaF3 cells harboring TEL-JAK2 measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| BaF3 | IC50 |
1430 nM
Compound: 28
|
Antiproliferative activity against mouse BAF3 cells expressing wild type JAK2 kinase after 72 hrs by alamar blue assay in presence of IL-3
Antiproliferative activity against mouse BAF3 cells expressing wild type JAK2 kinase after 72 hrs by alamar blue assay in presence of IL-3
|
[PMID: 19762238] |
| BaF3 | IC50 |
2425 nM
Compound: 28
|
Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK3 kinase after 72 hrs by alamar blue assay
Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK3 kinase after 72 hrs by alamar blue assay
|
[PMID: 19762238] |
| BaF3 | IC50 |
798 nM
Compound: 28
|
Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK2 kinase after 72 hrs by alamar blue assay
Antiproliferative activity against mouse BAF3 cells expressing TEL-JAK2 kinase after 72 hrs by alamar blue assay
|
[PMID: 19762238] |
| BaF3 | IC50 |
1.5 μM
Compound: 9, CYT387
|
Inhibition of JAK2 V617F mutant in mouse BAF3 cells
Inhibition of JAK2 V617F mutant in mouse BAF3 cells
|
10.1039/C1MD00175B |
| CMK | IC50 |
700 nM
Compound: CYT387
|
Antiproliferative activity against human CMK cells harboring JAK3A572V mutant measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against human CMK cells harboring JAK3A572V mutant measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| HCC1143 | IC50 |
5 μM
Compound: 91; CYT387
|
Anticancer activity against human HCC1143 cells assessed as cell growth inhibition
Anticancer activity against human HCC1143 cells assessed as cell growth inhibition
|
[PMID: 33650861] |
| HCC1187 | IC50 |
1 μM
Compound: 91; CYT387
|
Anticancer activity against human HCC1187 cells assessed as cell growth inhibition
Anticancer activity against human HCC1187 cells assessed as cell growth inhibition
|
[PMID: 33650861] |
| HCC70 | IC50 |
10 μM
Compound: 91; CYT387
|
Anticancer activity against human HCC70 cells assessed as cell growth inhibition
Anticancer activity against human HCC70 cells assessed as cell growth inhibition
|
[PMID: 33650861] |
| HEL | IC50 |
1804 nM
Compound: 28
|
Antiproliferative activity against human HEL 92.1.7 cells expressing JAK2 V617F mutant kinase after 72 hrs by alamar blue assay
Antiproliferative activity against human HEL 92.1.7 cells expressing JAK2 V617F mutant kinase after 72 hrs by alamar blue assay
|
[PMID: 19762238] |
| HEL | IC50 |
2.3 μM
Compound: 1; CYT-387
|
Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay
|
[PMID: 29940115] |
| HEL | IC50 |
0.95 μM
Compound: 1
|
Antiproliferative activity against HEL cells
Antiproliferative activity against HEL cells
|
[PMID: 38838918] |
| HL-60 | IC50 |
8.3 μM
Compound: 1; CYT-387
|
Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay
|
[PMID: 29940115] |
| K562 | IC50 |
58000 nM
Compound: CYT387
|
Antiproliferative activity against human K562 cells measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against human K562 cells measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| K562 | IC50 |
>20000 nM
Compound: 28
|
Antiproliferative activity against human K562 cells after 72 hrs by alamar blue assay
Antiproliferative activity against human K562 cells after 72 hrs by alamar blue assay
|
[PMID: 19762238] |
| K562 | IC50 |
6.5 μM
Compound: 1; CYT-387
|
Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay
|
[PMID: 29940115] |
| K562 | IC50 |
4.7 μM
Compound: 1
|
Antiproliferative activity against human K562 cells
Antiproliferative activity against human K562 cells
|
[PMID: 38838918] |
| MDA-MB-231 | IC50 |
1 μM
Compound: 91; CYT387
|
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition
Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition
|
[PMID: 33650861] |
| MDA-MB-468 | IC50 |
1 μM
Compound: 91; CYT387
|
Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition
Anticancer activity against human MDA-MB-468 cells assessed as cell growth inhibition
|
[PMID: 33650861] |
| MV4-11 | IC50 |
3000 nM
Compound: CYT387
|
Antiproliferative activity against human MV4-11 cells measured after 72 hrs by Alamar blue staining based analysis
Antiproliferative activity against human MV4-11 cells measured after 72 hrs by Alamar blue staining based analysis
|
[PMID: 19295546] |
| SET-2 | IC50 |
232 nM
Compound: 28
|
Antiproliferative activity against human SET2 cells expressing JAK2 V617F mutant kinase after 72 hrs by alamar blue assay
Antiproliferative activity against human SET2 cells expressing JAK2 V617F mutant kinase after 72 hrs by alamar blue assay
|
[PMID: 19762238] |
| THP-1 | IC50 |
8.8 μM
Compound: 1
|
Antiproliferative activity against human THP-1 cells
Antiproliferative activity against human THP-1 cells
|
[PMID: 38838918] |
Momelotinib (CYT387) inhibits the proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated by IL-3 with IC50 of 1400 nM. Furthermore, Momelotinib (CYT387) also causes the inhibition of cell proliferation in cell lines constitutively activated by JAK2 or MPL signaling, including Ba/F3-MPLW515L cells, CHRF-288-11 cells and Ba/F3-TEL-JAK2 cells with IC50 of 200 nM, 1 nM and 700 nM, respectively. In addition, Momelotinib (CYT387) has been shown to inhibit erythroid colony growth in vitro from JAK2V617F-positive PV patients with similar potency with IC50 of 2 μM-4 μM[1]. Momelotinib (CYT387) inhibits PI3K/AKT and Ras/MAPK signaling induced by IL-6 and IGF-1. Moreover, Momelotinib (CYT387) induces apoptosis as a single agent and synergizes with the conventional anti-MM therapies PS-341 and L-PAM in primary multiple myeloma (MM) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1056634-68-4
-
Appearance Solid
-
Masse moléculaire 414.46
-
Formule C23H22N6O2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1)NCC#N
-
Synonyms
CYT387
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
-
Cancer Cell
2018 Sep 10;34(3):439-452.e6. PMID: 30205046
Momelotinib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2018 Sep 10;34(3):439-452.e6. [Abstract]
Immunoblot (IB) of the indicated proteins in A549, H2009, HCC44, and H1792 cells treated with indicated concentration of Momelotinib (MMB) for 24 hr.
-
Cancer Res
Phosphorylation of RAB7 by TBK1/IKKε Regulates Innate Immune Signaling in Triple-Negative Breast Cancer. [Abstract]2020 Jan 1;80(1):44-56. PMID: 31662325
Momelotinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2020 Jan 1;80(1):44-56. [Abstract]
Immunofluorescence imaging of parental and Rab7 cell lines: WT, S72E, and S72A, treated with either 1 μM Compound 1 (6 h), 5 μM MRT67307 (8 h) or 5 μM Momelotinib (CYT387) (3 h) alone (representative, n=2; scale=10μm).
-
Nat Commun
PEAK1 maintains tight junctions in intestinal epithelial cells and resists colitis by inhibiting autophagy-mediated ZO-1 degradation. [Abstract]2025 Jul 24;16(1):6777. PMID: 40707483 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Leukemia
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]2012 Oct;26(10):2233-44. PMID: 22469781 -
Metabolism
Propagation of senescent phenotypes by extracellular HMGB1 is dependent on its redox state. [Abstract]2025 Apr 4:156259. PMID: 40189139 -
Int J Biol Sci
Rocaglamide promotes the infiltration and antitumor immunity of NK cells by activating cGAS-STING signaling in non-small cell lung cancer. [Abstract]2022 Jan 1;18(2):585-598. PMID: 35002511
Momelotinib purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Jan 1;18(2):585-598. [Abstract]
A549, H1299, H1975, and LLC cells were treated with or without 25 nM of RocA in the presence or absence of 5 µM Momelotinib (CYT387), or 10 µM BAY11 for 24 h, and then the expressions of CCL5 and CXCL10 were analyzed by real-time PCR.
-
Cell Death Dis
4EBP1 senses extracellular glucose deprivation and initiates cell death signaling in lung cancer. [Abstract]2022 Dec 27;13(12):1075. PMID: 36575176
Momelotinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Dec 27;13(12):1075. [Abstract]
A549 cells transfected with either control siRNA or 4EBP1 siRNAs were treated with Momelotinib (CYT387) or LY3214996 for 10 h in normal or glucose starvation conditions. Western blot analysis of p-STAT3 (Y705) expression. The results showed that CYT387 and LY3214996 could inhibit the phosphorylation of STAT3. Furthermore, the increased protein levels of p-STAT3 by knocking down 4EBP1 under GS were attenuated when treating with CYT387 or LY3214996 in A549 cells.
-
Cancer Immunol Res
2016 Jun;4(6):520-30. PMID: 27068336
Momelotinib purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2016 Jun;4(6):520-30. [Abstract]
CCL5 ELISA in 8988T-sgATG5 cells 24 h after a 60 min IL1β pulse ± 2.5 μM Momelotinib (CYT387) or ruxolitinib, mean and SD of duplicate samples shown.
Momelotinib purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2016 Jun;4(6):520-30. [Abstract]
H&E staining and IHC for CCL5, p62 or PD-L1 in pancreatic tissue harvested from C57/BL6 mice pretreated with vehicle control or daily Momelotinib (CYT387, 50 mg/kg; i.g.) day 1 post-cerulein. The results showed that CYT387 significantly inhibited the expression of CCL5 and PD-L1.
Momelotinib purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2016 Jun;4(6):520-30. [Abstract]
Inflammatory cell infiltration in pancreatic tissue from 3 random sites (200x) following vehicle (n = 4) or Momelotinib (CYT387, 50 mg/kg; i.g.; once daily for 2 days) (n = 2) treatment. Mean and SEM shown, P value calculated by Student t-test. The results demonstrated that CYT387 markedly reduced inflammatory cell infiltration following lanserin stimulation.
-
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
J Pineal Res
MicroRNA-7 inhibits melatonin synthesis by acting as a linking molecule between leptin and norepinephrine signaling pathways in pig pineal gland. [Abstract]2019 Apr;66(3):e12552. PMID: 30618087 -
J Enzyme Inhib Med Chem
Discovery and biological evaluation of a novel and highly potent JAK2 inhibitor for the treatment of triple negative breast cancer. [Abstract]2025 Dec;40(1):2488127. PMID: 40298145 -
J Biotechnol
2025 Mar:399:9-18. PMID: 39824361 -
J Clin Lab Anal
The Immunoregulatory and Hematopoietic Effects of Momelotinib in a Murine Bone Marrow Failure Model. [Abstract]2026 Feb;40(4):e70161. PMID: 41552919 -
Immunol Invest
CYT387 Inhibits the Hyperproliferative Potential of Fibroblast-like Synoviocytes via Modulation of IL-6/JAK1/STAT3 Signaling in Rheumatoid Arthritis. [Abstract]2022 Aug;51(6):1582-1597. PMID: 34704880 -
Environ Monit Assess
Assessment of the physicochemical characteristics of by-products of cassava processing and their effects on biodiversity. [Abstract]2025 Apr 10;197(5):533. PMID: 40208441 -
Solvant et solubilité
DMSO : 10 mg/mL (24.13 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Glutathione-S-transferase (GST)-tagged JAK kinase domains expressed in insect cells are purified before use in a peptide substrate phosphorylation assay. Assays are carried out in 384-well optiplates using an Alphascreen Protein Tyrosine Kinase P100 detection kit and a PerkinElmer Fusion Alpha instrument.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3-MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells are used. The TEL/JAK2 and TEL/JAK3 fusions are generated and introduced into Ba/F3 murine cells. The TEL/JAK2- or TEL/JAK3-transfected cells are cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Ba/F3 wild-type cells are cultured in RPMI containing 10% FCS supplemented with 5 ng/mL murine IL-3. Proliferation is measured using the Alamar Blue assay after incubating for 72 hours at 37°C with 5% CO2.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
On day 32 after bone marrow transplantation (when all mice exhibit severe leukocytosis and erythrocytosis), mice are assigned to 3 groups such that each group had equivalent average body weight and blood counts. Momelotinib (CYT387) is dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone). Subsequently, the CYT387/NMP mix is diluted with 0.14 M Captisol to a concentration of 6 mg/mL and further diluted with 0.1M Captisol to a final concentration of 4 mg/mL. All 3 groups of mice (n=12 per group) are administered Momelotinib (CYT387) by oral gavage twice daily at 10- to 12-hour intervals from day 34 after bone marrow transplantation to day 82 (end of experiment). Mice receive NMP/Captisol without Momelotinib (CYT387) (0 mg/kg group), 25 mg/kg Momelotinib (CYT387), or 50 mg/kg Momelotinib (CYT387). At day 82 after bone marrow transplantation, all mice are euthanized for analysis except for 2 mice each from the 50 mg/kg and 25 mg/kg groups, which are taken off Momelotinib (CYT387) treatment and followed for 45 additional days. For assessment of the effects of CYT387 on normal blood counts, naive Balb/c mice are administered vehicle control, 50 mg/kg, or 100 mg/kg Momelotinib (CYT387) in an identical fashion as described for the bone marrow transplant experimental mouse cohort. Peripheral blood is drawn at day 14, 28, 42, and 56 and levels of red cells, white cells, reticulocytes, granulocytes, lymphocytes, and monocytes are analyzed[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445. [Content Brief]
[2]. Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 2011, 25(12), 1891-1899. [Content Brief]
[3]. Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240. [Content Brief]
[4]. Kitajima S, et al.Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.Cancer Cell. 2018 Sep 10;34(3):439-452.e6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4128 mL | 12.0639 mL | 24.1278 mL | 60.3195 mL |
| 5 mM | 0.4826 mL | 2.4128 mL | 4.8256 mL | 12.0639 mL | |
| 10 mM | 0.2413 mL | 1.2064 mL | 2.4128 mL | 6.0319 mL | |
| 15 mM | 0.1609 mL | 0.8043 mL | 1.6085 mL | 4.0213 mL | |
| 20 mM | 0.1206 mL | 0.6032 mL | 1.2064 mL | 3.0160 mL |
Momelotinib Related Classifications
HY-10961 Related Classifications
Powered by Bioz